Hologic to Webcast Presentation at the Canaccord Genuity 39th Annual Growth Conference

MARLBOROUGH, Mass.–(BUSINESS WIRE)–#holx–Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Canaccord Genuity 39th Annual Growth Conference in New York, NY on Wednesday, August 7 at 10 a.m. Eastern Time.

The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcast will be available for 30 days following the event.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com

Source: Hologic, Inc.

Contacts

Paula Izidoro

Senior Investor Relations Specialist

(858) 410-8904

paula.izidoro@hologic.com

Staff

Recent Posts

UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026

CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…

4 hours ago

Best Ipamorelin vs Sermorelin: Growth Hormone Peptide Comparison 2026 — ReadyRx Prescription Telehealth Analysis

Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…

7 hours ago

GLP-1 Booster From Health Journey: 2026 Ingredient Analysis And Probiotic Metabolic Support Explained

Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…

7 hours ago

MEDVi GLP-1 Investigation: What Consumer Data Shows About Compounded Telehealth Weight Loss Programs

Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…

7 hours ago

Best Peptides for Anti-Aging: NAD+ Delivery Methods Compared as Telehealth Platforms Expand Access (2026 Analysis)

Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…

7 hours ago

Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a…

7 hours ago